Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. (GH) director Tariq Musa reported a small set of equity transactions involving company stock. On September 15, 2026, 249 Restricted Stock Units vested and were converted into 249 shares of common stock, increasing his directly held common shares. The same RSU award, granted on March 6, 2023, vests over four years, with 25% having vested on March 15, 2024 and the remaining 75% vesting monthly over the following three years, leaving 1,500 RSUs reported as outstanding after this vesting event. On September 16, 2026, he sold 116 shares of common stock at a reported price of $175.00 per share in a transaction affirmed as made under a Rule 10b5-1 trading plan.
Guardant Health, Inc. (GH) director Musa Tariq filed a notice of proposed sale under Rule 144 for 116 shares of common stock, to be sold through Charles Schwab & Co., Inc. The shares have an aggregate market value of $20,300, with Guardant Health reporting 134,196,170 shares outstanding as of September 16, 2026.
The 116 shares derive from equity compensation following a restricted stock lapse dated August 15, 2026. Over the prior three months, Tariq reported multiple sales of Guardant Health common stock totaling several hundred thousand dollars in aggregate proceeds.
Guardant Health, Inc. (GH) is the issuer for which director Alex M. Azar has filed a notice on Form 144 to potentially sell up to 826 shares of Guardant Health common stock. The shares relate to equity compensation, noted as a restricted stock lapse dated September 12, 2026, and the proposed sale through Charles Schwab & Co., Inc. on NASDAQ is listed with an aggregate market value of $144,550.00 as of September 16, 2026.
Guardant Health, Inc. (GH) director Steve E. Krognes has filed a notice of proposed sale under Rule 144 for up to 6,674 shares of Guardant Health common stock held at Charles Schwab & Co., Inc. The shares were acquired on June 12, 2025 through a restricted stock lapse as equity compensation, with an aggregate market value listed as $1,172,886. The stock is listed on NASDAQ, and the filing notes 134,196,170 shares of common stock outstanding and an approximate sale date of September 16, 2026.
Guardant Health, Inc. (GH) received a Rule 144 notice covering a proposed sale of restricted common stock by officer Darya Chudova. The notice states an intention to sell 7,738 shares of Guardant Health common stock through Charles Schwab & Co., Inc. on or after September 15, 2026 on NASDAQ.
The shares derive from equity compensation, described as a restricted stock lapse, and were acquired and paid for between March 1, 2025 and July 1, 2026. The filing lists an aggregate market value for the planned sale of $1,377,364 and indicates 134,196,170 shares of Guardant Health common stock outstanding.
Guardant Health, Inc. (GH) reported that director Alex M. Azar II had 1,651 Restricted Stock Units convert into 1,651 shares of Common Stock on September 12, 2026, at a stated price of $0.00 per share, reflecting a vesting event rather than a market sale.
The Restricted Stock Unit award was granted on September 12, 2025 and vests over four years, with 25% of the shares vesting on September 12, 2026 and the remaining 75% vesting monthly over the following three years. After this vesting, 4,953 Restricted Stock Units and 1,651 Common Stock shares are held directly, and no Rule 10b5-1 trading plan is reported.
Guardant Health, Inc. (GH) reported that Chief Information Officer Kumud Kalia sold 4,000 shares of common stock on September 11, 2026 in an open‑market or private transaction at a weighted average price of $158.0483 per share. After this sale, the officer directly held 39,794 shares of Guardant Health common stock. The sale price reflects multiple individual trades executed between $157.99 and $158.215 per share. No Rule 10b5-1 trading plan is reported for this transaction.
Guardant Health, Inc. (GH) has an officer, Kumud Kalia, filing a Rule 144 notice to sell 4,000 shares of common stock of Guardant Health through Charles Schwab & Co., Inc. The planned sale, listed on NASDAQ, is tied to shares acquired via equity compensation between April 1, 2025 and October 1, 2025.
The filing also reports that Kalia previously sold 3,418 shares of Guardant Health common stock on June 11, 2026 for aggregate proceeds of $445,156. The new 4,000-share sale is valued in the notice at $632,193 as of September 11, 2026.
Guardant Health, Inc. (GH) reported insider transactions by Co-Chief Executive Officer and director Helmy Eltoukhy involving only indirect holdings. On August 26, 2026, entities associated with him restructured 50,000 shares of common stock, moving 25,000 shares from the Helmy A. Eltoukhy Revocable Trust to The Eltoukhy Foundation, leaving the foundation holding 60,000 shares. The same trust also made a bona fide gift of 30,000 shares to a Donor Advisory Fund at Vanguard. All transactions were reported at a price of $0.00 per share and reflect ownership changes and charitable giving rather than market purchases or sales.
Guardant Health, Inc. (GH) reported that Co-Chief Executive Officer and director AmirAli Talasaz, through indirect ownership by the Talasaz Family Foundation, sold a total of 37,500 shares of common stock on August 21, 2026 in open-market or private transactions. The sales occurred in three weighted-average price tranches between $167.81 and $170.50 per share. The transactions were not reported as made under a Rule 10b5-1 trading plan.